Elicio Therapeutics Announces FDA Clearance of IND Application for ELI-002 — A Therapeutic Vaccine Targeting Mutated KRAS Cancers
Phase I/II Clinical Trial to Be Initiated in First Quarter 2021
CAMBRIDGE, Mass.–(BUSINESS WIRE)–#KRASmutation–Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph-node …